High Prevalence of Low Bone Mineral Density in Pre-dialysis Chronic Kidney Disease Patients: Bone Histomorphometric Analysis
Overview
Authors
Affiliations
Unlabelled: Chronic kidney disease (CKD) leads to reduced bone mineral density (BMD) in pre-dialysis and dialysis patients. A few studies have used dual-energy x-ray absorptiometry (DEXA) to assess BMD in pre-dialysis CKD patients and have shown low BMD to be highly prevalent. Until now there have been no studies reporting the histological features of low BMD in pre-dialysis CKD patients.
Aim: To determine the prevalence and histological features of low BMD in pre-dialysis CKD patients.
Method: Pre-dialysis CKD patients (n = 103, 46 females/57 males), median creatinine clearance of 29 (10 - 78) ml/min/ 1.73 m2, were evaluated using biochemical analysis and DEXA. Bone biopsies were obtained from those with low BMD.
Results: Fifty (48.5%) out of the 103 patients had low BMD (LBD group) and 53 (51.5%) had normal BMD (NBD group). The risk for low BMD was increased in those patients with alkaline phosphatase levels above 190 U/l and intact-PTH (iPTH) below 70 pg/ml (p < 0.05). Demographic and biochemical parameters from both groups were comparable, except for lower body mass index (BMI) in LBD subjects (p = 0.04). Women who had been post-menopausal for at least 1 year comprised 65% (13/20) and 50% (13/26) of the LBD and NBD groups, respectively (p = NS). In 40 LBD patients, bone histomorphometry revealed adynamic bone disease (ABD, 52.5%), osteomalacia (OM, 42.5%) and mixed bone disease (MBD, 5%). Trabecular bone volume (BV/TV) was lower in ABD and OM patients. A nearly significant association was found between ABD and iPTH < or = 150 pg/ml (p = 0.056), whereas higher values of iPTH were associated with OM. Total alkaline phosphatase < or = 190 U/l was significantly associated with ABD, whereas higher values were associated with OM. No correlation was observed between BV/TV and BMD.
Conclusion: Low BMD is frequent in pre-dialysis CKD patients, and low turnover bone disease, manifesting as ABD and OM, was the hallmark of this bone loss.
Liu Y, Zhang Z, Fu C, Ye Z, Jin H, Yang X BMC Nephrol. 2025; 26(1):68.
PMID: 39934684 PMC: 11818153. DOI: 10.1186/s12882-025-03992-w.
Lalayiannis A, Soeiro E, Moyses R, Shroff R Pediatr Nephrol. 2023; 39(3):723-739.
PMID: 37624528 PMC: 10817832. DOI: 10.1007/s00467-023-06109-3.
Bittencourt A, Canziani M, Costa L, Rochitte C, Carvalho A Bone Rep. 2022; 16:101166.
PMID: 35118180 PMC: 8792406. DOI: 10.1016/j.bonr.2022.101166.
Usmani S, Ahmed N, Gnanasegaran G, Marafi F, Van den Wyngaert T Skeletal Radiol. 2021; 51(5):905-922.
PMID: 34524489 DOI: 10.1007/s00256-021-03905-6.
Malmgren L, McGuigan F, Christensson A, Akesson K Osteoporos Int. 2017; 28(12):3463-3473.
PMID: 29038837 PMC: 5684332. DOI: 10.1007/s00198-017-4221-y.